Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date

References

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• World Health Organization/International Agency for Research on Cancer (WHO/IARC)GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012Online analysis on multiple myeloma Available from: globocan.iarc.frAccessed April 29, 2016
   Google Scholar
• MinaRCerratoCBernardiniAAghemoEPalumboANew pharmacotherapy options for multiple myelomaExpert Opin Pharmacother201617218119226684262
   PubMed Web of Science ®Google Scholar
• AyedAOChangLJMorebJSImmunotherapy for multiple myeloma: current status and future directionsCrit Rev Oncol Hematol201596339941226153389
   PubMed Web of Science ®Google Scholar
• BroijlASonneveldPAn update in treatment options for multiple myeloma in nontransplant eligible patientsExpert Opin Pharmacother201516131945195726245702
   PubMed Web of Science ®Google Scholar
• KumarSKDispenzieriALacyMQContinued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia20142851122112824157580
   PubMed Web of Science ®Google Scholar
• LaubachJGarderetLMahindraAManagement of relapsed multiple myeloma: recommendations of the International Myeloma Working GroupLeukemia20163051005101726710887
   PubMed Web of Science ®Google Scholar
• OcioEMRichardsonPGRajkumarSVNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Leukemia201428352554224253022
   PubMed Web of Science ®Google Scholar
• SondergeldPvan de DonkNWRichardsonPGPlesnerTMonoclonal antibodies in myelomaClin Adv Hematol Oncol201513959960926452191
   PubMedGoogle Scholar
• Van de DonkNWKampsSMutisTLokhorstHMMonoclonal antibody-based therapy as a new treatment strategy in multiple myelomaLeukemia201226219921321852787
   PubMed Web of Science ®Google Scholar
• MagarottoVSalviniMBonelloFBringhenSPalumboAStrategy for the treatment of multiple myeloma utilizing monoclonal antibodies: a new era beginsLeuk Lymphoma201657353755626445358
   PubMed Web of Science ®Google Scholar
• Van de DonkNWMoreauPPlesnerTClinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myelomaBlood2016127668169526631114
   PubMed Web of Science ®Google Scholar
• VeilletteASLAM-family receptors: immune regulators with or without SAP-family adaptorsCold Spring Harb Perspect Biol201023a00246920300214
   PubMed Web of Science ®Google Scholar
• GuoHCruz-MunozMEWuNRobbinsMVeilletteAImmune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cellsMol Cell Biol2015351415125312647
   PubMed Web of Science ®Google Scholar
• VeilletteAGuoHCS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myelomaCrit Rev Oncol Hematol201388116817723731618
   PubMed Web of Science ®Google Scholar
• Cruz-MunozMEDongZShiXZhangSVeilletteAInfluence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell functionNat Immunol200910329730519151721
   PubMed Web of Science ®Google Scholar
• HsiEDSteinleRBalasaBCS1, a potential new therapeutic antibody target for the treatment of multiple myelomaClin Cancer Res20081492775278418451245
   PubMed Web of Science ®Google Scholar
• TaiYTDillonMSongWAnti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuBlood200811241329133717906076
   PubMed Web of Science ®Google Scholar
• KumaresanPRLaiWCChuangSSSBennettMMathewPACS1, a novel member of the CD2 family, is homophilic and regulates NK cell functionMol Immunol2002391–21812213321
   PubMed Web of Science ®Google Scholar
• BolesKSSteppSEBennettMKumarVMathewPA2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytesImmunol Rev200118123424911513145
   PubMed Web of Science ®Google Scholar
• BolesKSMathewPAMolecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamilyImmunogenetics2001523–430230711220635
   PubMed Web of Science ®Google Scholar
• BouchonACellaMGriersonHLCohenJIColonnaMActivation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 familyJ Immunol2001167105517552111698418
   PubMed Web of Science ®Google Scholar
• Pérez-QuinteroLARoncagalliRGuoHLatourSDavidsonDVeilletteAEAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarizationJ Exp Med2014211472774224687958
   PubMed Web of Science ®Google Scholar
• XieZGunaratneJCheongLLPlasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myelomaOncotarget2013471008101823900284
   PubMed Web of Science ®Google Scholar
• GlaveySReagynMManierSDissecting the mechanisms of activity of SLAMF7 and the targeting antibody elotuzumab in multiple myelomaBlood201412421343125267198
   PubMed Web of Science ®Google Scholar
• CollinsSMBakanCESwartzelGDElotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCCCancer Immunol Immunother201362121841184924162108
   PubMed Web of Science ®Google Scholar
• BalasaBYunRBelmarNAElotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathwaysCancer Immunol Immunother2015641617325287778
   PubMed Web of Science ®Google Scholar
• ZonderJAMohrbacherAFSinghalSA phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaBlood2012120355255922184404
   PubMed Web of Science ®Google Scholar
• Van RheeFSzmaniaSMDillonMCombinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaMol Cancer Ther2009892616262419723891
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (U.S.), FDA-approved drug productsEMPLICITI Center for Drug Evaluation and Research (CDER) Summary Review 2015 Available from: http://www.fda.govAccessed April 29, 2016
   Google Scholar
• MalekASagerRKuhnPNicolaidesKHSchneiderHEvolution of maternofetal transport of immunoglobulins during human pregnancyAm J Reprod Immunol19963652482558955500
   PubMed Web of Science ®Google Scholar
• JakubowiakAJBensonDMBensingerWPhase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myelomaJ Clin Oncol201230161960196522291084
   PubMed Web of Science ®Google Scholar
• LonialSVijRHarousseauJLElotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaJ Clin Oncol201230161953195922547589
   PubMed Web of Science ®Google Scholar
• PostelnekJSheridanJKellerSEffects of elotuzumab on soluble SLAMF7 levels in multiple myeloma. American Society of Hematology Annual Meeting 2015Blood201512623 abstract 2964
   Google Scholar
• GibianskyLPasseyCRoyABelloAGuptaMModel-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myelomaJ Pharmacokinet Pharmacodyn201643324325726993283
   PubMed Web of Science ®Google Scholar
• PasseyCGibianskyLMoraJRoyABelloAGuptaMEffect of dexamethasone co-administration on the pharmacokinetics and immunogenicity of elotuzumabClin Pharmacol Ther201699S86
   Web of Science ®Google Scholar
• BerdejaJJagannathSZonderJPharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib studyClin Lymphoma Myeloma Leuk201616312913826795075
   PubMed Web of Science ®Google Scholar
• RichardsonPGJagannathSMoreauPElotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation studyLancet Haematol2015212e516e52726686406
   PubMed Web of Science ®Google Scholar
• LonialSDimopoulosMPalumboAElotuzumab therapy for relapsed or refractory multiple myelomaN Engl J Med2015373762163126035255
   PubMed Web of Science ®Google Scholar
• LagrueKCariseyAMorganDJChopraRDavisDMLenalidomide augments actin remodeling and lowers NK-cell activation thresholdsBlood20151261506026002964
   PubMed Web of Science ®Google Scholar
• KotlaVGoelSNischalSMechanism of action of lenalidomide in hematological malignanciesJ Hematol Oncol200923619674465
   PubMed Web of Science ®Google Scholar
• BenboubkerLDimopoulosMADispenzieriALenalidomide and dexamethasone in transplant-ineligible patients with myelomaN Engl J Med20143711090691725184863
   PubMed Web of Science ®Google Scholar
• DimopoulosMSpencerAAttalMLenalidomide plus dexamethasone for relapsed or refractory multiple myelomaN Engl J Med2007357212123213218032762
   PubMed Web of Science ®Google Scholar
• WeberDMChenCNiesvizkyRLenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaN Engl J Med2007357212133214218032763
   PubMed Web of Science ®Google Scholar
• WeiselKDoyenCDimopoulosMA systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantationLeuk Lymphoma201619
   Web of Science ®Google Scholar
• DimopoulosMAEloquent-2 update: A phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma – 3-year safety and efficacy follow-upBlood20151262328
   Google Scholar
• HallettWHAmesEMotarjemiMSensitization of tumor cells to NK cell-mediated killing by proteasome inhibitionJ Immunol2008180116317018097016
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med2003348262609261712826635
   PubMed Web of Science ®Google Scholar
• JagannathSBarlogieBBerensonJA phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBr J Haematol2004127216517215461622
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• San MiguelJFSchlagRKhuagevaNKBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med2008359990691718753647
   PubMed Web of Science ®Google Scholar
• ScottKHaydenPJWillAWheatleyKCoyneIBortezomib for the treatment of multiple myelomaCochrane Database Syst Rev20164CD01081627096326
   PubMed Web of Science ®Google Scholar
• JakubowiakAOffidaniMPégourieBRandomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) versus Bd for relapsed/refractory multiple myelomaBlood2016127232833284027091875
   PubMed Web of Science ®Google Scholar
• PalumboAOffidaniMPégourieBElotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: 2-year follow-upBlood201512623510
   Web of Science ®Google Scholar
• WengWKLevyRTwo immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphomaJ Clin Oncol200321213940394712975461
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa geneBlood200299375475811806974
   PubMed Web of Science ®Google Scholar
• MateosMVElotuzumab for treating multiple myelomaExp Opin Orphan Drugs201642215222
   Web of Science ®Google Scholar
• PalumboASonneveldPPreclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myelomaExpert Rev Hematol20158448149126070331
   PubMed Web of Science ®Google Scholar
• DimopoulosMALonialSWhiteDEloquent-2 update: A phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma – 3-year safety and efficacy follow-upBlood20151262328
   Google Scholar
• BerensonJSwiftRHobsonSRifkinRElotuzumab administered over approximately 60 minutes in combination with lenalidomide and dexamethasone in patients with multiple myeloma: a phase 2 safety studyHematology/Oncology Pharmacy Association (HOPA) 12th Annual ConferenceMarch 16–19, 2016Atlanta, GA Poster No. 312016
   Google Scholar
• SwiftRHobsonSRifkinRBerensonJElotuzumab administered over approximately 60 minutes in combination with lenalidomide and dexamethasone in patients with multiple myeloma: a phase 2 safety studyOncology Nursing Society 41st Annual CongressApril 28–May 1, 2016San Antonio, TX Poster No. E59
   Google Scholar
• DimopoulosMATerposENiesvizkyRPalumboAClinical characteristics of patients with relapsed multiple myelomaCancer Treat Rev2015411082783526296679
   PubMed Web of Science ®Google Scholar